Dr. Thomas E. Hutson on results of phase 3 CLEAR trial of pembrolizumab/lenvatinib in RCC

The immunotherapy/TKI combination significantly improved overall survival versus sunitinib.

Thomas E. Hutson, DO, PharmD, Texas Oncology‐Baylor Charles A. Sammons Cancer Center, discusses findings from the phase 3 CLEAR trial, in which frontline therapy with pembrolizumab (Keytruda) plus lenvatinib (Lenvima) reduced the risk of death by 34% versus sunitinib (Sutent) in patients with advanced renal cell carcinoma (RCC). The combination also improved progression-free survival (PFS) and response compared with sunitinib. In the trial, it was also demonstrated that combining lenvatinib and everolimus improved PFS and objective response rate but not OS versus sunitinib in this setting (J Clin Oncol. 2021; 39[suppl6]:269. doi: 10.1200/JCO.2021.39.6_suppl.269).

Related Videos
Dr. Brian Rini in an interview
Bradley McGregor, MD, answers a question during a video interview
Dr. Sarah Psutka in an interview
Dr. Thomas Hutson in an interview at the ASCO annual meeting
Dr. Camilo Arenas-Gallo in an interview with Urology Times
Dr. Larissa Rodriguez in an interview with Urology Times
© 2023 MJH Life Sciences

All rights reserved.